Brief: Sagimet Biosciences Estimates Its Cash, Cash Equivalents, Short-Term Investments In Marketable Securities Were About $94.9 Million
24/01/2024 11:23
Jan 24 (Reuters) - Sagimet Biosciences Inc SGMT.O :
* SAGIMET BIOSCIENCES-ON JAN 23,ESTIMATES CASH, CASH
EQUIVALENTS,
SHORT-TERM INVESTMENTS IN MARKETABLE SECURITIES WERE ABOUT$94.9
MILLION AS OF DEC 31,2023
* SAGIMET BIOSCIENCES - CO'S ACTUAL RESULTS FOR YEAR ENDED
DEC 31,
2023 WILL BE INCLUDED IN CO'S ANNUAL REPORT ON FORM 10-K FOR
YEAR ENDED DEC 31, 2023
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage